Plural Nitrogens Nonionically Bonded Patents (Class 514/564)
-
Publication number: 20140221488Abstract: The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.Type: ApplicationFiled: December 16, 2013Publication date: August 7, 2014Applicant: CYDEX PHARMACEUTICALS, INC.Inventors: James D. Pipkin, Stephen G. Machatha
-
Patent number: 8796336Abstract: The present invention is directed generally to protecting cells, tissues and organs against the damaging effects of ionizing or other damaging agents associated with radiation or chemotherapy, or degenerative diseases or processes of various organs that elicit the production of free radicals or oxidants such as peroxides, superoxide anions, hydroxyl radicals or nitric oxides, or heavy metal cations. More particularly, the present invention is concerned with methoxypolyethylene glycol chelate methyl esters that are useful as protectors against tissue damage by penetrating the cell membrane to donate electrons to free radical oxidants and remove heavy metals that may react with peroxides to produce the reactive hydroxyl radical, or remove Ca++ that may be released from organelles. These chelate esters will also have utility in reducing intraocular pressure in glaucoma patients.Type: GrantFiled: July 22, 2011Date of Patent: August 5, 2014Assignee: Eastern Virginia Medical SchoolInventors: Karl A. Schellenberg, Frank A. Lattanzio, James Shaeffer
-
Publication number: 20140213650Abstract: The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: CYDEX PHARMACEUTICALS, INC.Inventors: James D. Pipkin, Stephen G. Machatha
-
Patent number: 8785497Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include a balance of ingredients that allow for the formation of ophthalmic compositions that include an anionic drug and exhibit desired characteristics such as stability, preservation efficacy, desired pH, desired osmolality, combinations thereof or the like.Type: GrantFiled: April 14, 2010Date of Patent: July 22, 2014Assignee: Alcon Research, Ltd.Inventor: Bhagwati P. Kabra
-
Patent number: 8778911Abstract: A polyamine-depleted food compositions is provided for preparing foods, intended for humans or animals, for preventing or treating heart rate anomalies.Type: GrantFiled: January 10, 2007Date of Patent: July 15, 2014Assignee: Universite De Rennes 1Inventors: Jacques Moulinoux, Jean-Pie'rre Estebe
-
Patent number: 8778998Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof, wherein R1-R23 are independently selected from the group consisting of hydrogen and deuterium; and at least one of R1-R23 is deuterium.Type: GrantFiled: April 9, 2010Date of Patent: July 15, 2014Assignee: Auspex Pharmaceuticals, Inc.Inventor: Chengzhi Zhang
-
Publication number: 20140178358Abstract: The present invention concerns means and methods for predicting the risk of a subject to suffer from liver damage. In particular, it pertains to a method for predicting the risk of a subject to suffer from liver damage caused by acetaminophen comprising determining the amount of putrescine in a blood, serum or plasma sample that has been obtained from the subject after administration of acetaminophen, and comparing the determined amount to a reference, whereby the risk of the subject to suffer from liver damage caused by acetaminophen is predicted. Also provided are devices for carrying out the aforementioned methods.Type: ApplicationFiled: December 20, 2013Publication date: June 26, 2014Applicants: The United States of America as represented by the Secretary of Department of Health and Human Servi, Metanomics Health GmbHInventors: Alexander Strigun, Lisette Leonhardt, Dörthe Ahlbory-Dieker, Lisa M. Pence, Richard Beger
-
Publication number: 20140179783Abstract: The invention provides an easy-to-drink beverage that contains citrulline, wherein the generation of bad odors due to storage or heating is suppressed. In particular, the invention provides a beverage that contains citrulline, citric acid, sodium citrate, water, and one or more supplements that are saccharides, souring agents, preservatives, colorants, flavoring agents, functional ingredients, or carbon dioxide.Type: ApplicationFiled: February 7, 2014Publication date: June 26, 2014Applicant: Kyowa Hakko Bio Co., Ltd.Inventors: Yasushi SAKAI, Takeshi IKEDA, Ayako KAMIMURA
-
Publication number: 20140162996Abstract: One aspect of the disclosure relates to derivatives of aryl and heterocyclic ureido aryl and heterocyclic carboxamido isobutyric acids, dichlorophenyl urea, curcumin, and 1,3-diazetidine-2,4-dione, and pharmaceutical compositions thereof. The derivatives disclosed herein can modulate development of adipocytes and various cancer cells, including resistant cancer cells and cancer stem cells. Another aspect of the disclosure relates to the use of the derivatives and pharmaceutical compositions disclosed herein in treatment of obesity and various cancers.Type: ApplicationFiled: July 29, 2013Publication date: June 12, 2014Applicant: CITY OF HOPEInventors: Samuel RAHBAR, James L. FIGAROLA, Christopher LINCOLN, David HORNE, Rachael MOONEY, Monika POLEWSKI, George SOMLO, Lixin YANG
-
Publication number: 20140135396Abstract: The invention is directed to the treatment of patients at risk for liver damage due to the overingestion of acetaminophen by administering agents that increase hepatic levels of nitric oxide.Type: ApplicationFiled: July 4, 2012Publication date: May 15, 2014Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Wolfram Goessling, Andrew Cox, Trista North
-
Publication number: 20140113884Abstract: Compounds and compositions comprising epoxyeicosatrienoic acid (EET) analogs that act as EET agonists and are useful as medications in the treatment of drug-induced nephrotoxicity, hypertension and other related conditions. Methods of making and using the compounds and compositions are further described.Type: ApplicationFiled: April 4, 2012Publication date: April 24, 2014Inventors: John David Imig, William B. Campell, John Russell Falck
-
Publication number: 20140107085Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.Type: ApplicationFiled: October 10, 2013Publication date: April 17, 2014Applicant: The Trustees of The University of PennsylvaniaInventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter
-
Publication number: 20140088156Abstract: The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.Type: ApplicationFiled: February 14, 2012Publication date: March 27, 2014Applicant: The Regents of the University of CaliforniaInventors: Bruce D. Hammock, Sung Hee Hwang, Aaron T. Wecksler, Christophe Morisseau
-
Publication number: 20140057878Abstract: The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: November 1, 2013Publication date: February 27, 2014Applicant: ALLERGAN, INC.Inventors: Wenkui K. Fang, Liming Wang, Evelyn G. Corpuz, Ken Chow, WhaBin Im
-
Publication number: 20140056862Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and ?-ketoglutarate. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.Type: ApplicationFiled: April 18, 2012Publication date: February 27, 2014Applicant: Nestec S.A.Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
-
Publication number: 20140044685Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and citrulline. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, ?-keto-glutarate, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.Type: ApplicationFiled: April 18, 2012Publication date: February 13, 2014Applicant: NESTEC S.A.Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
-
Patent number: 8592438Abstract: A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect.Type: GrantFiled: March 16, 2009Date of Patent: November 26, 2013Assignee: Sumitomo Chemical Intellectual Property Service, LtdInventors: Masanao Takaishi, Norio Kimura
-
Publication number: 20130310458Abstract: The present invention relates to a cell which is genetically modified with respect to its wild type and which comprises a gene sequence coding for an autofluorescent protein, wherein the expression of the autofluorescent protein depends on the intracellular concentration of a particular metabolite. The present invention also relates to a method for the identification of a cell having an increased intracellular concentration of a particular metabolite, a method for the production of a cell which is genetically modified with respect to its wild type with optimized production of a particular metabolite, a cell obtained by this method, a method for the production of metabolites and a method for the preparation of a mixture.Type: ApplicationFiled: May 3, 2011Publication date: November 21, 2013Inventors: Lothar Eggeling, Michael Bott, Stephan Binder, Julia Frunzke, Nurije Mustafi
-
Publication number: 20130280330Abstract: A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH3O—[CH2—CH2—O]m—[C(O)—CH(CH3)—O]n—R (I).Type: ApplicationFiled: July 30, 2010Publication date: October 24, 2013Applicant: XI'AN LIBANG MEDICAL TECHNOLOGY CO., LTD.Inventors: Renle Hu, Jiucheng Wang, Tao Chen, Hua Liang, Duohao Ding, Yaqi Jiao
-
Publication number: 20130274261Abstract: Methods of treating pulmonary hypertension are disclosed. Particular methods comprise the administration of a tryptophan hydroxylase inhibitor and a prostacyclin. Pharmaceutical formulations are also disclosed.Type: ApplicationFiled: March 18, 2013Publication date: October 17, 2013Inventor: Arthur T. SANDS
-
Patent number: 8557869Abstract: This invention provides diets useful for promoting fat loss in animals having a total lysine to metabolizable energy ratio of from about 6 to about 10 g/Mcal. This invention also provides compositions for promoting fat loss in animals, methods for preparing the compositions, methods for using the diets and compositions, articles of manufacture comprising the diets and compositions, and means for communicating information or instructions about such diets, compositions, methods, and articles of manufacture.Type: GrantFiled: August 5, 2009Date of Patent: October 15, 2013Assignee: Hill's Pet Nutrition, Inc.Inventors: Ryan Michael Yamka, Kim Gene Friesen
-
Patent number: 8557868Abstract: The present invention relates to a lens care solution comprising: 0.001 to about 5 weight percent of a low molecular weight amine of the general formula: Where R1, R2, R3 and R4 are —H or low molecular weight radicals, and R5 is a low molecular weight radical, or salt thereof; an effective amount of tonicity agent; and the balance water.Type: GrantFiled: November 14, 2002Date of Patent: October 15, 2013Assignee: FXS Ventures, LLCInventor: Francis X. Smith
-
Patent number: 8546448Abstract: A process for forming a solid electrolytic capacitor and an electrolytic capacitor formed by the process. The process includes: providing an anode wherein the anode comprises a porous body and an anode wire extending from the porous body; applying a thin polymer layer onto the dielectric, and forming a dielectric on the porous body to form an anodized anode; applying a first slurry to the anodized anode to form a blocking layer wherein the first slurry comprises a first conducting polymer with an median particle size of at least 0.05 ?m forming a layer of crosslinker on the blocking layer; and applying a layer of a second conducting polymer on the layer of crosslinker.Type: GrantFiled: September 15, 2011Date of Patent: October 1, 2013Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel, Ramchandran Arudchandran, Rita O'Neil
-
Publication number: 20130251818Abstract: Personal lubricants containing royal jelly, a glow powder or xylitol are provided.Type: ApplicationFiled: March 22, 2013Publication date: September 26, 2013Applicant: Nature Labs USA LLCInventors: Louis J. Rivers, IV, Kevin Stranen
-
Publication number: 20130244952Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.Type: ApplicationFiled: October 11, 2012Publication date: September 19, 2013Applicant: Abraxis BioScience, LLCInventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
-
Publication number: 20130237577Abstract: Composition comprising leucine, isoleucine, valine, threonine and lysine for use in prophylactic and/or therapeutic treatment of renal disorders in a subject, preferably an elderly subject.Type: ApplicationFiled: January 12, 2011Publication date: September 12, 2013Inventors: Francesco Saverio Dioguardi, Edoardo Carlo Maria Conti, Giovanni Federico Maria Conti, Isabella Arborio Mella
-
Publication number: 20130237571Abstract: The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are therefore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.Type: ApplicationFiled: July 20, 2011Publication date: September 12, 2013Applicant: Conexios Life Sciences PVT. LTD.Inventors: Jagannath Madanahalli Ranganath Rao, Nagarajan Arumugam, Mohd Mudabbir Ansari, Chandrasekhas Gudla, Shanmugam Pachiyappan, Manivannan Ramalingam, Jenson George, George Fernanda Arul, Kenchegowda Bommegowda, Y, Sathesh Kumar Angupillai, Ramamoorthy Kottamalai, Pradeep Jidugu, Shivanageshwara Rao, D
-
Publication number: 20130225517Abstract: The invention provides compounds of formula I: or salts thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I and therapeutic methods for treating cancer.Type: ApplicationFiled: February 22, 2013Publication date: August 29, 2013Applicant: University of Iowa Research FoundationInventor: University of Iowa Research Foundation
-
Publication number: 20130216634Abstract: An extraction method for extracts of Pelargonium citronellum with improved methylhexaneamine content is provided. The method involves separating the oil phase from the aqueous phase; concentrating the aqueous phase; purifying the oil phase; and recombining the resulting material. Additionally, extracts of Pelargonium citronellum prepared by the extraction method are provided. The extracts are useful in compositions, for example as dietary supplements, and for appetite suppression.Type: ApplicationFiled: March 12, 2013Publication date: August 22, 2013Inventors: James Akrong, Shawn Shirazi, Jason Peters, John Doherty
-
MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
Publication number: 20130217706Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease; and other diseases.Type: ApplicationFiled: September 13, 2012Publication date: August 22, 2013Applicant: ARENA PHARMACEUTICALS, INC.Inventors: Thuy-Anh Tran, Weichao Chen, Bryan A. Kramer, Abu J.M. Sadeque, Anna Shifrina, Yoúng-Jun Shin, Pureza Vallar, Ning Zou -
Publication number: 20130217743Abstract: Controlling exogenous polyamines may be used, in some aspects, as an adjunctive strategy to chemoprevention with polyamine inhibitory agents, for example, anti-carcinoma combination therapies comprising ornithine decarboxylase (ODC) inhibitor and a spermidine/spermine N1-acetyltransferase expression agonist, optionally based on a patient's ODC1 promoter genotype. Assessing a tissue polyamine level or tissue polyamine flux may be used in some aspects, for predicting the efficacy of an anti-carcinoma combination therapy comprising, for example, an ornithine decarboxylase (ODC) inhibitor and an agent that modulates the polyamine pathway to reduce overall cellular polyamine content.Type: ApplicationFiled: May 13, 2011Publication date: August 22, 2013Applicants: CANCER PREVENTION PHARMACEUTICALS, INC., CANCER PREVENTION PHARMACEUTICAL, INC, THE REGENT OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATIONInventors: Kavitha P. Raj, Jason A. Zell, Christine E. Mclaren, Eugene W. Gerner, Frank L. Meyskens, JR., Jeffrey Jacob
-
Publication number: 20130209433Abstract: Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyper-VLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal.Type: ApplicationFiled: December 12, 2012Publication date: August 15, 2013Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Albert Einstein College of Medicine of Yeshiva University
-
Publication number: 20130209446Abstract: Provided herein are methods of diagnosing and/or treating malignant or pre-malignant conditions in a subject. Overexpression of copy number variant-dependent genes, e.g., genes encoding a cell surface receptor, resulting from copy number changes compared to control is diagnostic of the condition, such as multiple myeloma or monoclonal gammopathy of undetermined significance. Also provided are methods for treating malignant conditions, such as multiple myeloma or a hyperdiploid subtype, with therapeutic agents, with or without other anti-cancer drugs, to downrregulate the overexpressed CNV genes and/or up-regulate the underexpressed genes. Furthermore, methods for lowering drug resistance in multiple myeloma cells via inhibition of platelet activation or thrombin release and for increasing survivability of a multiple myeloma subject via lithibition of PSMD4 gene to increase b-catenin protein expression are provided.Type: ApplicationFiled: July 20, 2011Publication date: August 15, 2013Applicant: Board of Trustees of the University of ArkansasInventors: John D. Shaughnessy, JR., Bart Barlogie, Erming Tian, Yiming Zhou
-
Publication number: 20130197088Abstract: The present invention is based on the seminal discovery of a synergistic effect for combinations of oligoamines with 2-difluoromethylornithine (DFMO) for treatment of cancer. The invention provides combinations of at least one inhibitor of a histone demethylase enzyme and at least one inhibitor of ornithine decarboxylase (ODC). The invention also provides methods for treatment of cancer using such combinations and methods for altering methylation in a cell using such combinations. The invention provides that certain silenced genes can be re-expressed using combinations disclosed herein.Type: ApplicationFiled: March 11, 2011Publication date: August 1, 2013Inventors: Robert A. Casero, JR., Laurence J. Marton
-
Patent number: 8475813Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: November 21, 2011Date of Patent: July 2, 2013Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou
-
Publication number: 20130158036Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: ApplicationFiled: November 1, 2012Publication date: June 20, 2013Applicant: PANMIRA PHARMACEUTICALS, LLCInventor: PANMIRA PHARMACEUTICALS, LLC
-
Patent number: 8466198Abstract: The invention relates to compositions (e.g., nutritional supplements) comprising, consisting essentially of, or consisting of a creatine bicarbonate, and to methods of making and using said compositions.Type: GrantFiled: September 2, 2008Date of Patent: June 18, 2013Inventor: Bruce Kneller
-
Publication number: 20130142768Abstract: The present invention relates to a method for promoting eye health by administering to a companion animal a composition comprising at least one polyphenol selected from the group consisting of rosemary, rosemary extract, coffeic acid, coffee extract, turmeric extract, cucurmin, blueberry extract, grapeseed extract, rosemarinic acid, tea extract, and mixtures thereof.Type: ApplicationFiled: February 1, 2013Publication date: June 6, 2013Applicant: THE IAMS COMPANYInventor: The IAMS Company
-
Publication number: 20130137635Abstract: This invention relates to tryptophan hydroxylase inhibitors, compositions comprising them, and methods of their use for the treatment, management and/or prevention of metastatic bone disease.Type: ApplicationFiled: February 9, 2011Publication date: May 30, 2013Applicant: LEXICON PHARMACEUTICALS, INC.Inventor: Arthur Thomas Sands
-
Publication number: 20130131174Abstract: An injectable pharmaceutical formulation of Melphalan comprising a solid composition of melphalan hydrochloride lyophilized with a content of impurities up to 1.3% (p/p)and a pH buffer solution; a process to prepare said solid composition. Also a reconstituted solution of melphalan comprising a solid composition of melphalan lyophilized reconstituted wherein said solution is aqueous, a perfusion free of organic solvent and a kit.Type: ApplicationFiled: July 4, 2011Publication date: May 23, 2013Applicant: ERIOCHEMInventors: José Castillo, José Bernardo Iturraspe, José Lucio Nuñez
-
Publication number: 20130123364Abstract: The present invention describes the use of N6-(1-iminoethyl)-L-lysine for the manufacture of a medicament for the treatment of pulmonary alveolar damage or destruction in mammals, including in humans.Type: ApplicationFiled: January 9, 2013Publication date: May 16, 2013Inventor: Norbert Weissmann
-
Publication number: 20130121969Abstract: The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo curing with low heat generation to form materials suitable for use in scaffolds in tissue engineering applications such as bone and cartilage repair. The polymers are desirably flowable and injectable and can support living biological components to aid in the healing process. They may be cured ex-vivo for invasive surgical repair methods, or alternatively utilized for relatively non-invasive surgical repair methods such as by arthroscope. The invention also relates to prepolymers useful in the preparation of the polymeric compositions, and to methods of treatment of damaged tissue using the polymers of the invention.Type: ApplicationFiled: October 31, 2012Publication date: May 16, 2013Applicant: POLYNOVO BIOMATERIALS PTY LIMITEDInventors: Raju Adhikari, Pathiraja Arachchillage Gunatillake
-
Publication number: 20130121937Abstract: Provided is a composition including, as an active ingredient, at least one selected from the group consisting of amines, amides and polyols. The cosmetic composition has an effect of preventing aging and may be applied in various industrial fields, including cosmetics.Type: ApplicationFiled: June 22, 2011Publication date: May 16, 2013Inventors: Hyeon Chung Kim, Hyun Hee Kim, Sung Il Park, Youn Joon Kim, Sang Hoon Han
-
Publication number: 20130123345Abstract: Described herein is a method of treating a viral infection such as an influenza infection, in a subject comprising administering an effective amount of a pharmaceutical composition to disrupt a adenosine receptor pathway, such as the Aradenosine receptor pathway, in a subject. The adenosine receptor pathway includes the steps of 1) producing the adenosine precursor adenosine triphosphate (ATP), 2) releasing ATP into the extracel lular space, 3) enzymatic conversion of ATP to adenosine, 4) activation of the adenosine receptor and the adenosine receptor cascade, and 5) clearance of adenosine from the extracellular space by degradation or uptake into a cell. The method includes affecting at least one of these steps so as to decrease the activation of the adenosine receptor pathway. This may be accomplished by decreasing the production, release, or conversion of ATP to adenosine, decreasing the expression of the adenosine receptor, antagonizing adenosine receptor activation, and/or increasing adenosine clearance.Type: ApplicationFiled: July 22, 2011Publication date: May 16, 2013Applicant: THE OHIO STATE UNIVERSITYInventor: Ian C. Davis
-
Publication number: 20130116192Abstract: N-(aminoacyl)-amino compound, represented by the following formula Wherein R1 denotes hydrogen, low alkyl or carbonyl, and N1 denotes an NH group and R2 denotes hydrogen or low alkylphenyl or aralkyl or imidazoalkyl or indolylalkyl, R1 and R2 together may complete a pyrrolidine or piperidine or thiazolidine ring and R3 denotes hydrogen or methyl or low alkyl and R4 denotes hydrogen or alkyl or the group remaining on exclusion of R4 from the formula and Z is a straight chain or branched alkylene, which may contain up to 3 carbon atoms. and R5 is nitrogen or sulphur or oxygen or salts thereof and ester compounds, characterised in that A is an ester or amino acid or alternatively sodium or a potassium salt of arginate and/or of ornithate and/or of aspharaginate.Type: ApplicationFiled: March 30, 2011Publication date: May 9, 2013Inventor: Gosbert Weth
-
Publication number: 20130104881Abstract: Pharmaceutical pressurized metered dose inhalers are disclosed having improved temperature and moisture stability comprising CFC-free, ethanol-free compositions that include lactose of particle diameter larger than 1 ?m as a means of minimizing sticking to the walls and other destabilization mechanisms activated by moisture ingress from the environment.Type: ApplicationFiled: October 31, 2011Publication date: May 2, 2013Applicant: Laboratorio Pablo Cassara S.R.L.Inventors: Fernando Toneguzzo, Julio Cesar Vega
-
Publication number: 20130071439Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using D-amino acids are described.Type: ApplicationFiled: January 10, 2011Publication date: March 21, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Richard Losick, Jon Clardy, Roberto Kolter, Illana Kolodkin-Gal, Diego Romero, Shugeng Cao
-
Patent number: 8399425Abstract: The invention discloses methods of using cis-epoxyeicosantrienoic acids (“EETs”), inhibitors of soluble epoxide hydrolase (“sEH”), or a combination of an EET and an inhibitor of sEH, to alleviate neuropathic pain in subjects suffering from such pain.Type: GrantFiled: November 7, 2008Date of Patent: March 19, 2013Assignee: The Regents of the University of CaliforniaInventors: Bruce D. Hammock, Ahmet Bora Inceoglu, Steven L. Jinks
-
Publication number: 20130059096Abstract: A method of treating, reducing, or inhibiting biofilm formation by bacteria, the method comprising: contacting an article with a composition comprising an effective amount of a D-amino acid, said composition being essentially free of the corresponding L-amino acid, thereby treating, reducing or inhibiting formation of the biofilm, wherein the D-amino acid is selected from the group consisting of D-alanine, D-cysteine, D-aspartic acid, D-glutamic acid, D-histidine, D-isoleucine, D-lysine, D-leucine, D-asparagine, D-proline, D-glutamine, D-arginine, D-serine, D-threonine, D-valine, D-tryptophan, D-tyrosine, and a combination thereof.Type: ApplicationFiled: January 10, 2011Publication date: March 7, 2013Applicant: President and Fellows of Harvard CollegeInventors: Richard Losick, Jon Clardy, Roberto Kolter, Illana Kolodkin-Gal, Diego Romero, Shugeng Cao
-
Publication number: 20130035390Abstract: Disclosed are methods for treating multiple sclerosis patients that entail co-administration of effective amounts of a Ras antagonist which is farnesylthiosalicylic acid or an analog thereof, and a second active agent selected from glatiramer acetate, laquinimod and combinations thereof. Therapeutic compositions and methods of making them are also disclosed.Type: ApplicationFiled: January 13, 2011Publication date: February 7, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Elizabeta Aizman, Joab Chapman